Amorcyte is a biopharm company engaged in the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine primarily in the United States. Its lead product candidate, AMR-001, which is for the prevention of major adverse cardiac events … Continue reading →

Athersys is a clinical stage biopharm company growing a pipeline of highly differentiated therapeutics to treat significant and life-threatening diseases. The company’s current product development portfolio consists of MultiStem®, a proprietary stem cell product for the treatment of multiple disease … Continue reading →

OncoSec Medical is a biotech company focused on the development of treatments addressing advanced-stage skin cancer, specifically: melanoma, Merkel cell lymphoma and cutaneous T-cell lymphoma. ONCS’ proprietary technology, OncoSec Medical System™ (OMS), is based on electroporation and in pre-clinical and … Continue reading →

Neuralstem, a development-stage company focused on the development and commercialization of treatments for central nervous system disease, has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area … Continue reading →

ProMetic Life Sciences operates through a group of subsidiaries to specialize in the design of small molecules that mimic unique and specific interactions between proteins. The company’s technologies are applicable to large-scale drug purification, drug development, proteomics and the elimination … Continue reading →

NovaBay Pharmaceuticals is a clinical-stage biotech company focused on the development of its proprietary and patented Aganocide® compounds. NBY focuses its technology on four therapeutic areas: dermatology, ophthalmology, urology and hospital infections. The company has entered into and recently expanded … Continue reading →

Shire is a biopharmaceutical company that focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas. SHPG’s in-licensing, merger and acquisition efforts are focused on products … Continue reading →

Organovo Holdings focuses on breakthrough 3D biology capabilities to create tissue on-demand for research and surgical applications. The company’s NovoGen MMX Bioprinter™ is the world’s only commercial bioprinter with the proven ability to create tissue. The novel and flexible capabilities … Continue reading →

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is developing RVX-208 for the treatment of atherosclerosis. RVX’s business model is to seek strategic opportunities through early alliance partnerships with the … Continue reading →

Cytori Therapeutics is a medical technologies company focused on the potential of adult stem cell and regenerative cells from adipose tissue. The company’s Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic … Continue reading →